The National Pharmaceutical Pricing Authority (NPPA) on November 05, 2026, revised the Maximum Retail Prices of Non-Scheduled Anti-Cancer Drugs – Effective November 9, 2026.
NPPA has revised the Maximum Retail Prices (MRPs) of various non-scheduled anti-cancer drug formulations, based on data received from pharmaceutical companies up to November 5, 2026. The revised list covers formulations of Abemaciclib, Abiraterone Acetate, Acalabrutinib and Afatinib, among others, across different strengths, brands and pack sizes. Several formulations have witnessed substantial reductions in their MRPs, while certain products, including Ramiven (Abemaciclib), have retained their existing prices.
The revised MRPs will come into effect from November 9, 2026, and the respective manufacturers are required to ensure that the formulations are marketed at the revised prices.
